CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Receives Average Recommendation of "Hold" from Analysts theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
CymaBay Therapeutics (NASDAQ:CBAY) Now Covered by Analysts at StockNews.com themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Results from a phase 3 trial looking at treatment for primary biliary cholangitis (PBC) are 'genuinely exciting' and support the potential for seladelpar to raise the bar in treatment of the disease.
Fred Alger Management LLC Makes New Investment in CymaBay Therapeutics, Inc. (NASDAQ:CBAY) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
CymaBay Therapeutics (CBAY) Announces Publication of Positive Phase 3 RESPONSE Data of Seladelpar streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.